Veracyte (VCYT) Aktievy
Veracyte, Inc. bedriver verksamhet som diagnostikföretag i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för VCYT från våra riskkontroller.
VCYT Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Veracyte, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$57.08 |
| 52 veckors högsta | US$60.91 |
| 52 veckors lägsta | US$22.61 |
| Beta | 1.93 |
| 1 månads förändring | 17.14% |
| 3 månaders förändring | 76.61% |
| 1 års förändring | 107.49% |
| 3 års förändring | 140.74% |
| 5 års förändring | 50.33% |
| Förändring sedan börsintroduktionen | 330.79% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 02
VCYT: Raised Guidance And New Cancer Tests Will Drive Medium Term Story
Veracyte's updated analyst price target has shifted higher from $53.00 to about $67.60, as analysts factor in revised assumptions around profitability, reimbursement stability in its Afirma and Decipher testing assets, and potential contribution from newer platforms such as molecular residual disease and Prosigna. Analyst Commentary Recent research on Veracyte points to a generally constructive tone, with several bullish analysts updating their models and price targets in light of company discussions and revised assumptions around its testing portfolio.Analysartikel • Jun 19
Veracyte (VCYT) Stock Could Be 4.5% Overvalued After Its Recent Run
Veracyte (VCYT) has drawn attention after recent share price gains over the past month and the past 3 months, prompting a closer look at how its diagnostics business and current valuation might align with investor expectations. See our latest analysis for Veracyte. At a share price of $51.29, Veracyte has seen short term momentum build, with a 30 day share price return of 23.59% feeding into a 1 year total shareholder return of 91.24% and a 3 year total shareholder return of 98.34%. If...
Uppdatering av berättelse • Jun 18
VCYT: MRD And Prosigna Execution Risks Will Restrain Future Stock Repricing
Veracyte’s analyst price target has increased by $5 to $55, with analysts highlighting the company’s Afirma and Decipher testing assets, along with potential contributions from molecular residual disease and Prosigna, as key supports for this updated view. Analyst Commentary Recent research on Veracyte highlights a mix of optimism around Afirma, Decipher, and emerging opportunities such as molecular residual disease and Prosigna, alongside reminders that sentiment is not uniformly positive.
Uppdatering av berättelse • Jun 04
VCYT: Updated Models And Trial Readouts Will Shape Post 2026 Outlook
Veracyte's analyst price target has been raised from $47.00 to $49.10. Analysts generally point to the perceived resilience of its Afirma and Decipher testing assets, along with potential upside from additional testing platforms, as key factors supporting the updated view.Recent updates
Uppdatering av berättelse • Jul 02
VCYT: Raised Guidance And New Cancer Tests Will Drive Medium Term Story
Veracyte's updated analyst price target has shifted higher from $53.00 to about $67.60, as analysts factor in revised assumptions around profitability, reimbursement stability in its Afirma and Decipher testing assets, and potential contribution from newer platforms such as molecular residual disease and Prosigna. Analyst Commentary Recent research on Veracyte points to a generally constructive tone, with several bullish analysts updating their models and price targets in light of company discussions and revised assumptions around its testing portfolio.Analysartikel • Jun 19
Veracyte (VCYT) Stock Could Be 4.5% Overvalued After Its Recent Run
Veracyte (VCYT) has drawn attention after recent share price gains over the past month and the past 3 months, prompting a closer look at how its diagnostics business and current valuation might align with investor expectations. See our latest analysis for Veracyte. At a share price of $51.29, Veracyte has seen short term momentum build, with a 30 day share price return of 23.59% feeding into a 1 year total shareholder return of 91.24% and a 3 year total shareholder return of 98.34%. If...Uppdatering av berättelse • Jun 18
VCYT: MRD And Prosigna Execution Risks Will Restrain Future Stock Repricing
Veracyte’s analyst price target has increased by $5 to $55, with analysts highlighting the company’s Afirma and Decipher testing assets, along with potential contributions from molecular residual disease and Prosigna, as key supports for this updated view. Analyst Commentary Recent research on Veracyte highlights a mix of optimism around Afirma, Decipher, and emerging opportunities such as molecular residual disease and Prosigna, alongside reminders that sentiment is not uniformly positive.Uppdatering av berättelse • Jun 04
VCYT: Updated Models And Trial Readouts Will Shape Post 2026 Outlook
Veracyte's analyst price target has been raised from $47.00 to $49.10. Analysts generally point to the perceived resilience of its Afirma and Decipher testing assets, along with potential upside from additional testing platforms, as key factors supporting the updated view.Uppdatering av berättelse • May 20
VCYT: Mixed Price Revisions Will Pressure Expectations For Future Cash Flow Repricing
Narrative Update Veracyte's updated analyst price target shifts to $37.23 from $38.59, as analysts factor in a slightly higher discount rate, more moderate revenue growth expectations, a higher projected profit margin, and a lower assumed future P/E multiple, informed by recent mixed target revisions and a new bullish initiation. Analyst Commentary Recent research on Veracyte reflects a split view, with some firms turning more constructive while several bearish analysts have trimmed price targets and highlighted execution and valuation risks.Analysartikel • May 14
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s ( NASDAQ:VCYT...Uppdatering av berättelse • Apr 28
VCYT: Revised Street Views Will Highlight Medium Term Revenue Guidance Story
Analysts now see a modestly lower upside for Veracyte, trimming the consensus price target by a few dollars to around the mid $30s. Recent research reflects a balance between reduced targets from several firms and a newer bullish initiation that emphasizes the company's longer term growth potential.Uppdatering av berättelse • Apr 14
VCYT: Bullish Coverage And Margin Reset Will Strengthen Prostate Cancer Risk Position
Analysts now see Veracyte's fair value at $53, up from $51. This revision reflects updated assumptions around growth, profitability and valuation multiples informed by recent Street research, including both fresh coverage and revised price targets.Uppdatering av berättelse • Mar 31
VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside
Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results.Uppdatering av berättelse • Mar 17
VCYT: NCCN Risk Stratification Focus Will Support Future Cash Flow Repricing
Analysts have lowered their price target on Veracyte from $43.00 to about $38.59, citing updated assumptions for revenue growth, profit margins and future P/E following recent model revisions. This includes a reduced $37 target from one large Wall Street firm after Q4 results.Uppdatering av berättelse • Mar 02
VCYT: 2026 Revenue Outlook And Higher Future P/E Will Lift Long-Term Upside
Analysts now set their Veracyte price target at $48.60, compared with $47.50 previously. This reflects updated views on revenue growth, profit margin assumptions and a higher future P/E multiple.Uppdatering av berättelse • Feb 16
VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role
Analysts have kept their $51.00 price target for Veracyte unchanged, citing updated assumptions that reflect slightly lower discount rates, modestly higher revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Veracyte issued earnings guidance for the fourth quarter of 2025, with expected total revenue between US$138 million and US$140 million, described as 16% to 18% growth for the period.Uppdatering av berättelse • Feb 02
VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption
Narrative Update on Veracyte Analysts have kept their Veracyte fair value target steady at $43.00, citing updated NCCN prostate cancer guidelines that highlight Decipher’s role in risk stratification and support slightly adjusted assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Recent commentary points to the updated NCCN prostate cancer guidelines as a supportive data point for Veracyte’s Decipher test.Uppdatering av berättelse • Jan 19
VCYT: NCCN Guideline Support Will Strengthen Prostate Cancer Risk Stratification Role
Analysts have lifted their price target on Veracyte from US$45.00 to US$51.00, citing updated NCCN guidelines that they view as incrementally favorable for the company’s Decipher prostate cancer test and its differentiation based on clinical evidence. Analyst Commentary Bullish analysts are framing the latest NCCN prostate cancer guideline update as a meaningful support for Veracyte’s Decipher test, especially around how it is positioned within risk stratification.Seeking Alpha • Jan 16
Veracyte: Profitable, De-Risked, And Ready To Run
Summary Veracyte (VCYT) has transitioned to a profitable, diversified model with strong operating leverage and self-fortifying balance sheet. Key 2025-2026 catalysts include deeper prostate cancer penetration, entry into minimal residual disease, and U.S. re-launch of the Prosigna breast cancer test. VCYT projects 16% revenue growth to $515–$517M in FY25 and >25% adjusted EBITDA margin, signaling sustained profitable execution. A robust digital pathology database and AI-driven bioinformatics platform create significant competitive moats and future product opportunities. Read the full article on Seeking AlphaUppdatering av berättelse • Jan 05
VCYT: NCCN Guideline Support Will Shape Future Decipher Adoption And Competitive Risks
Analysts have lifted their price target on Veracyte from $28.40 to $43.00, citing updated NCCN prostate cancer guidelines that highlight the Decipher test in key risk stratification tables as support for a higher fair value assumption. Analyst Commentary Analysts point to the updated NCCN V3.2026 prostate cancer guidelines as a supportive data point for Veracyte, highlighting that Decipher is explicitly listed in the principles of risk stratification tables across several key prostate cancer settings.Uppdatering av berättelse • Dec 15
VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption
Analysts have modestly raised their price target on Veracyte to approximately $47.50 from about $46.30, citing slightly stronger long term growth and profitability expectations, as well as the incremental boost from updated NCCN guidelines that further differentiate the company’s Decipher prostate cancer test. Analyst Commentary Street research characterizes the NCCN guideline update as a net positive for Veracyte, with the Decipher prostate cancer test receiving prominent placement in risk stratification tables across multiple disease stages.Uppdatering av berättelse • Nov 29
VCYT: New NCCN Guidelines Will Support Continued Market Differentiation
Analysts have raised their price target for Veracyte from $45.30 to $46.30, citing ongoing positive inclusion of the company’s Decipher test in updated clinical guidelines as a contributing factor. Analyst Commentary Analysts have examined the recent updates to the clinical guidelines and their implications for Veracyte’s Decipher test, highlighting both opportunities and potential challenges facing the company.Analysartikel • Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Veracyte, Inc. ( NASDAQ:VCYT ) shares have been powering on, with a gain of 27% in the...Uppdatering av berättelse • Nov 15
VCYT: Expanded Prostate Cancer Guidelines Will Drive Demand Ahead
Veracyte's analyst price target has been raised from $41.10 to $45.30. Analysts cite stronger guidelines support, as well as improved revenue and profit growth expectations, as key drivers.Uppdatering av berättelse • Nov 01
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.Uppdatering av berättelse • Oct 18
Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets
Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.Analysartikel • Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders would be excited to see that the share price has had a great month, posting...Analysartikel • Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Veracyte, Inc. ( NASDAQ:VCYT ) is a stock worth...Analysartikel • May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
As you might know, Veracyte, Inc. ( NASDAQ:VCYT ) just kicked off its latest quarterly results with some very strong...Ny berättelse • May 07
Decipher, Afirma And MRD Tests Will Broaden Future Markets
Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.Analysartikel • Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Even though Veracyte, Inc. ( NASDAQ:VCYT ) posted strong earnings, investors appeared to be underwhelmed. We have done...Analysartikel • Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Analysartikel • Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Key Insights Veracyte's estimated fair value is US$65.48 based on 2 Stage Free Cash Flow to Equity Veracyte is...Seeking Alpha • Dec 11
Veracyte: Getting Frothy
Summary Veracyte has seen its stock more than double since early August, driven by strong Q3 results and increased revenue guidance for FY2024. This medical diagnostic firm focused on oncology is executing well, but the stock looks a bit 'frothy' based on some valuation metrics. The analyst community is also somewhat mixed based on the stock's valuation, and there was some notable insider selling following Q3 results. Can the rally continue in Veracyte? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Veracyte, Inc. ( NASDAQ:VCYT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...Analysartikel • Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders have had their patience rewarded with a 42% share price jump in the last...Analysartikel • Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Shareholders will be ecstatic, with their stake up 39% over the past week following Veracyte, Inc. 's ( NASDAQ:VCYT...Analysartikel • Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Key Insights The projected fair value for Veracyte is US$37.52 based on 2 Stage Free Cash Flow to Equity Veracyte's...Analysartikel • Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Veracyte, Inc.'s ( NASDAQ:VCYT ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...Analysartikel • May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Veracyte, Inc. ( NASDAQ:VCYT ) investors will be delighted, with the company turning in some strong numbers with its...Aktieägarnas avkastning
| VCYT | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -5.6% | 4.1% | 1.6% |
| 1Y | 107.5% | 41.1% | 18.6% |
Avkastning vs industri: VCYT översteg US Biotechs branschen som gav 41.1 % under det senaste året.
Avkastning vs Marknaden: VCYT översteg US marknaden som gav 18.6 % under det senaste året.
Prisvolatilitet
| VCYT volatility | |
|---|---|
| VCYT Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: VCYT har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: VCYT s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2006 | 755 | Marc Stapley | www.veracyte.com |
Veracyte, Inc. är verksamt som ett diagnostikföretag i USA och internationellt. Företaget erbjuder Afirma Genomic Sequencing Classifier för cancerknölar i sköldkörteln, Decipher Prostate Genomic Classifiers för diagnos av prostatacancer, Decipher Bladder Genomic Classifier för diagnos av blåscancer, Prosigna Breast Cancer Assay för diagnos av bröstcancer och Percepta Nasal Swab Test för diagnos av lungcancer. Företaget tillhandahåller även tjänster inom analyssystemet nCounter.
Veracyte, Inc. Sammanfattning av grunderna
| VCYT grundläggande statistik | |
|---|---|
| Börsvärde | US$4.55b |
| Vinst(TTM) | US$88.01m |
| Intäkter(TTM) | US$541.74m |
51.7x
P/E-förhållande8.4x
P/S-förhållandeÄr VCYT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| VCYT resultaträkning (TTM) | |
|---|---|
| Intäkter | US$541.74m |
| Kostnad för intäkter | US$146.77m |
| Bruttovinst | US$394.97m |
| Övriga kostnader | US$306.96m |
| Intäkter | US$88.01m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 1.10 |
| Bruttomarginal | 72.91% |
| Nettovinstmarginal | 16.25% |
| Skuld/egenkapitalförhållande | 0% |
Hur har VCYT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/05 22:45 |
| Aktiekurs vid dagens slut | 2026/07/02 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Veracyte, Inc. bevakas av 24 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |